A described final dosage form includes a substance carrying a medicament in a first medicament-release state having a first bioavailability. The substance is modifiable ex vivo by an exposure to a first stimulus to carry the medicament in a second medicament-release state having a second bioavailability. The substance is modifiable ex vivo by an exposure to a second stimulus to carry the medicament in a third medicament-release state having a third bioavailability. The final dosage form includes another substance carrying another medicament in another first medicament-release state having another first bioavailability. The another substance is modifiable ex vivo by an exposure to another first stimulus to carry the another medicament in another second medicament-release state having another second bioavailability. The another substance is modifiable ex vivo by an exposure to another second stimulus to carry the another medicament in another third medicament-release state having another third bioavailability.
申请公布号
US2010068256(A1)
申请公布日期
2010.03.18
申请号
US20090387311
申请日期
2009.04.29
申请人
SEARETE LLC, A LIMITED LIABILITY CORPORATION OF THE STATE OF DELAWARE
发明人
BANGERA MAHALAXMI GITA;BOYDEN EDWARD S.;HYDE RODERICK A.;ISHIKAWA MURIEL Y.;RIVET DENNIS J.;SWEENEY ELIZABETH A.;WOOD, JR. LOWELL L.;WOOD VICTORIA Y.H.